Article
Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2005
O'Hare Thomas, Walters Denise K, Stoffregen Eric P, Sherbenou Daniel W, Heinrich Michael C, Deininger Michael W N, Druker Brian J
Abstract excerpt
PURPOSE: Chronic myeloid leukemia (CML) is effectively treated with imatinib. However, reactivation of Bcr-Abl via kinase domain mutations that reduce sensitivity to imatinib can cause relapse. As combination therapy is frequently used to prevent emergence of resistance, the combination of imatinib with an inhibitor of imatinib-resistant Bcr-Abl mutants (e.g., Src/Abl inhibitors AP23848 and BMS-354825) was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.